SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

OS Therapies updates OST-HER2 metastatic osteosarcoma program

OS Therapies, Inc. said it provided an update on its OST-HER2 metastatic osteosarcoma program and announced upcoming conference attendance by its management team and business development advisors.

OSTX

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories